钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭中的应用：向心肾双重保护的范式转变。
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection.
机构信息
Centre d'Investigation Clinique Pierre Drouin -INSERM - CHRU de Nancy, Institut lorrain du cœur et des vaisseaux Louis Mathieu, Nancy, France.
Centre d'Investigation Clinique Pierre Drouin -INSERM - CHRU de Nancy, Institut lorrain du cœur et des vaisseaux Louis Mathieu, Nancy, France.
出版信息
Heart Fail Clin. 2022 Oct;18(4):561-577. doi: 10.1016/j.hfc.2022.03.006.
Sodium-glucose transport inhibitors (SGLT2i) have been found to be effective in preventing heart failure in patients with diabetes or chronic kidney disease with or without cardiovascular disease. Recent evidence suggests that SGLT2i substantially improve cardiovascular and renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF). In this review, we discuss the combined cardio-renal benefits of SGLT2i in patients with HFrEF. In addition, we discuss the impact of renoprotection in the midterm management of HFrEF and possible implementation strategies for initiating SGLT2i in routine care of HFrEF.
钠-葡萄糖协同转运蛋白抑制剂（SGLT2i）已被证实可有效预防糖尿病或伴有或不伴有心血管疾病的慢性肾脏病患者发生心力衰竭。最近的证据表明，SGLT2i 可显著改善射血分数降低的心力衰竭（HFrEF）患者的心血管和肾脏结局。在本综述中，我们讨论了 SGLT2i 在 HFrEF 患者中的联合心肾获益。此外，我们还讨论了在 HFrEF 的中期管理中肾保护的影响，以及在 HFrEF 的常规治疗中启动 SGLT2i 的可能实施策略。
Zotero 插件